Inpatient to Outpatient: Myelofibrosis Care
Pharmacists discuss challenges in transitioning myelofibrosis patients between inpatient and outpatient care settings, emphasizing medication reconciliation and seamless inter-team communication.
EP: 1.Myelofibrosis Care: Pharmacist Role and Treatment Challenges
EP: 2.Blood Shortages Impacting Myelofibrosis Care
EP: 3.Challenges in Myelofibrosis: Red Blood Cell Transfusion Shortages
EP: 4.Impact and Adoption of Momelotinib in Myelofibrosis
EP: 5.Emerging Therapies and Momelotinib Impact
EP: 6.Inpatient to Outpatient: Myelofibrosis Care
EP: 7.Challenges in Outpatient Transition For Myelofibrosis Care
EP: 8.Navigating Myelofibrosis Transitions
EP: 9.Pharmacist-Led Patient Education Strategies
EP: 10.Addressing Socioeconomic Barriers in Myelofibrosis Care
EP: 11.Patient Advocacy in Myelofibrosis Care
EP: 12.Tailoring Myelofibrosis Care: Patient Preferences and Challenges
EP: 13.Advancements in Myelofibrosis Care: Pharmacists' Perspectives
This is a video synopsis/summary of a Peer Exchange involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; Shawn Griffin, PharmD, BCOP; and Robert Mancini, PharmD, BCOP, FHOPA.
In this segment, Mahmoudjafari discusses with Mancini the challenges of transitioning myelofibrosis patients from inpatient to outpatient care. They emphasize the importance of addressing medication access issues during transitions, especially for oral agents. Medication reconciliation is crucial, and Mancini highlights the pharmacist’s role in managing this process, ensuring timely prescriptions, and minimizing gaps in care. Nachar adds insights from the University of Michigan, emphasizing the need for a patient-centric approach, directly involving patients and interdisciplinary teams in reconciling medications. The discussion also covers the role of pharmacists in facilitating seamless communication and collaboration between inpatient and outpatient teams, ensuring all stakeholders are aware of therapy modifications. Griffin outlines the key players in this transition and emphasizes the need for effective communication, considering the reason for admission and potential modifications to therapy. The segment underscores the vital role pharmacists play in managing these transitions and optimizing care for myelofibrosis patients.
This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.
